JMAHP is moving to Taylor & Francis.

Please submit your manuscript here.

What makes a compliant Phase III and pre-launch patient advocacy strategy? Nick Hicks, Keith Allan, Christoph Thalheim, Paul Woods
A training paradigm to enhance performance and safe use of an innovative neuroendovascular device Donald R. Ricci, Thomas R. Marotta, Howard A. Riina, Martina Wan, Joost De Vries
Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement Michael Schlander, Silvio Garattini, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol Solà-Morales, Keith Tolley, Mondher Toumi
The quality of life of Spanish patients with Huntington’s disease measured with H-QoL-I and EQ-5D Julie Dorey, Emilie Clay, Amine Khemiri, Anis Belhadj, Patricia Trigo Cubillo, Mondher Toumi
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials Eve Hanna, Cecile Rémuzat, Pascal Auquier, Mondher Toumi
Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles Edward Gibson, Najida Begum, Federico Martinón-Torres, Marco Aurélio Safadi, Alfred Sackeyfio, Judith Hackett, Sankarasubramanian Rajaram

Metrics & Indexing

As a new journal, Journal of Market Access is not yet fully indexed. The Publisher is currently following a strategy to ensure quality indexing in line with other Co-Action Publishing titles.

Learn more